- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03938987
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)
A Phase 1b/2 Multi-center, De-centralized, Dose Selection Study of Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m^2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
Phase 1b: Dose Finding/Escalation Dose Level 1: 0.5 x 10^6/kg Dose Level 2: 1.0 x 10^6/kg Dose Level 3: 2.0 x 10^6/kg
Phase 2: Expansion Patients will receive lymphodepleting chemotherapy as indicated prior to receiving the CAR T-cell intravenous, single dose administration on Day 0 at the RP2D as identified during Phase 1b.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Zack Breckenridge
- Phone Number: 7803917687
- Email: zackariah.breckenridge@ahs.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N2T9
- Not yet recruiting
- Foothills Medical Centre
-
Contact:
- Dr. Andrew Daly, MD
-
Calgary, Alberta, Canada, T2N4N2
- Not yet recruiting
- Tom Baker Cancer Centre
-
Contact:
- Dr. Peter Duggan, MD
-
Calgary, Alberta, Canada, T3B6A8
- Not yet recruiting
- Alberta Children's Hospital
-
Contact:
- Dr. Victor Lewis, MD
-
Edmonton, Alberta, Canada, T6G1Z2
- Recruiting
- Cross Cancer Institute
-
Contact:
- Dr. Michael P Chu, MD
-
Edmonton, Alberta, Canada, T6G2B7
- Recruiting
- University of Alberta Hospital
-
Contact:
- Dr. Peng Wang, MD
-
Edmonton, Alberta, Canada, T6G2B7
- Not yet recruiting
- Stollery Children's Hospital
-
Contact:
- Dr. Sunil Desai, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have given written informed consent prior to any study-specific procedures; children (defined as 17 years of age or less) require guardian consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; or Karnofsky > 50%.
- Age of 2 to 70 years at time of screening.
- A histologically or cytologically documented, CD19+ non-hodgkin's lymphoma or ALL.
- At least 1 measurable lesion or FDG-avid disease by positron-emission tomography/computed tomography (PET/CT) for lymphoma patients; quantifiable evidence of ALL in either peripheral blood or bone marrow aspirate.
- Tumor tissue (archival or recent acquisition) must be available for correlative laboratory studies (such as immunohistochemistry, and others).
- At least 2 prior systemic therapies and patient must not be eligible for potentially curative standard-of-care therapy.
- Adequate renal function (defined as Cockroft-Gault creatinine clearance > 50 mL/min) and hepatic function (total bilirubin < 1.5x ULN; and AST/ALT < 3x ULN) unless directly related to malignant disease being treated for on study as demonstrated either by PET/CT imaging or by biopsy and histopathologic confirmation.
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of study treatment. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- Male participants should agree to not donate sperm during study period (i.e. up to 2 years following CAR T-cell administration).
- Male participants with reproductive potential must agree to use medical approved contraceptives during the study and for 90 days following the last dose of study treatment.
- Are reliable and willing to make themselves available for the duration of the study, and are willing to follow study procedures.
Exclusion Criteria:
- Prior treatment with immunotherapy directly targeting T-cells (except anti-thymocyte globulin [ATG]), CD19-directed antibody-based therapies (except blinatumomab), or other gene therapy products.
- Received any investigational drug/anti-cancer therapy within 30 days.
- Concurrent participation in another therapeutic clinical trial.
- Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to blood collection for CAR T-cell product manufacture.
- Donor lymphocyte infusion (DLI) within 4 weeks prior to leukapheresis.
- Salvage or debulking chemotherapy within 1 week prior to blood collection for CAR T-cell product manufacture.
- Prior central nervous system (CNS) involvement.
- Unresolved acute toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 Grade >1 (or baseline, whichever is greater) from prior anticancer therapy. Alopecia and other nonacute toxicities are acceptable.
- An uncontrolled intercurrent illness including but not limited to ongoing or active infection (including fever within 48 hours of screening), symptomatic congestive heart failure (i.e., New York Heart Association [NYHA] Class 3 or 4), unstable angina pectoris, clinically significant and uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Major surgical procedure within 30 days.
- Known history of human immunodeficiency virus (HIV) or active infection requiring therapy, or positive tests for hepatitis B surface antigen or hepatitis C ribonucleic acid (RNA).
- Any vaccination against infectious diseases (e.g., influenza, varicella) within 4 weeks (28 days) of initiation of study treatment.
- A woman who is pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR T cells
Patients with relapsed/refractory B-cell ALL or NHL.
|
Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).
All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and type of treatment-related adverse events.
Time Frame: 3 years
|
3 years
|
Number of dose limiting toxicities of anti-CD19 CAR T-cells
Time Frame: 3 years
|
3 years
|
Maximum concentration (Cmax).
Time Frame: 3 years
|
3 years
|
Time to maximum concentration (Tmax).
Time Frame: 3 years
|
3 years
|
Area-Under-the-Concentration-vs-time curve (AUC) in peripheral blood and/or bone marrow.
Time Frame: 3 years
|
3 years
|
Overall objective response rate (ORR: proportion of patients with confirmed responses of complete [CR] or partial [PR])
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr. Michael P Chu, MD, Cross Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACIT001/EXC002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed Non Hodgkin Lymphoma
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
NYU Langone HealthMerck Sharp & Dohme LLCTerminatedRelapsed Non-Hodgkin Lymphoma | Relapsed Hodgkin LymphomaUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
The First Affiliated Hospital of Soochow UniversityShanghai Unicar-Therapy Bio-medicine Technology Co.,LtdRecruitingRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin LymphomaChina
-
Joseph TuscanoSpectrum Pharmaceuticals, IncActive, not recruitingRelapsed Non Hodgkin Lymphoma | Refractory Non Hodgkin LymphomaUnited States
-
GC Cell CorporationUnknownRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin LymphomaKorea, Republic of
-
Loyola UniversityCompletedRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin LymphomaUnited States
-
Chinese PLA General HospitalShenzhen University General Hospital; Shenzhen UniversityUnknownRefractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
Clinical Trials on autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Peking Union Medical College HospitalCellular Biomedicine Group Ltd.CompletedB-cell Non-Hodgkin LymphomaChina
-
National Taiwan University HospitalNot yet recruitingRelapsed/Refractory B-Cell Malignancies
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalRecruiting
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingMantle Cell LymphomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingLymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell LymphomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.RecruitingLymphoma, Non-Hodgkin | Diffuse Large B Cell LymphomaChina
-
Stephan Grupp MD PhDChildren's Hospital of PhiladelphiaRecruitingB Cell Acute Lymphoblastic Leukemia (B-ALL) | B Lineage Lymphoblastic LymphomaUnited States
-
Innovative Cellular Therapeutics Co., Ltd.UnknownLymphoma, B-Cell | Leukemia, B-CellChina
-
Peking UniversityPeking University Cancer Hospital & InstituteRecruitingB Cell Non-Hodgkin's LymphomaChina
-
Hebei Senlang Biotechnology Inc., Ltd.Tongji HospitalRecruiting19 and 22+ B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic TumorsChina